Italia markets open in 6 hours 43 minutes

Dow Jones
39.869,38
-38,62(-0,10%)
Nasdaq
16.698,32
-44,07(-0,26%)
Nikkei 225
38.920,26
0,00(0,00%)
EUR/USD
1,0865
-0,0005(-0,04%)
Bitcoin EUR
60.152,16
-1.029,10(-1,68%)
CMC Crypto 200
1.373,22
-20,83(-1,49%)

NBIX May 2024 115.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

25,78

0,00

(0,00%)

In data: 12:10PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat